Study of Lanreotide in Patients With Metastatic Gastrointestinal Neuroendocrine Tumors Who Are Undergoing Liver-directed Radioembolization With Yttrium-90 Microspheres

NCT02859064 · clinicaltrials.gov ↗

PHASE2

Phase

TERMINATED

Status

6

Enrollment

OTHER

Sponsor class

Stopped Closed due to slow accrual

Conditions

Neuroendocrine Tumors
Gastrointestinal Neoplasms
Carcinoid Tumors

Interventions

DRUG: Lanreotide
DEVICE: Y-90 microspheres

Sponsor

SCRI Development Innovations, LLC

Collaborators

[object Object]